How to Cite
1.
Villanea CF. Hormone Replacement Therapy: Window of Opportunity. Rev.méd.sinerg. [Internet]. 2019Jan.1 [cited 2024Jul.2];4(1):14 - 22. Available from: https://revistamedicasinergia.com/index.php/rms/article/view/166
Abstract
It exhibits a review on the Hormone Replacement Therapy (HRT), intending to promote the criteria on the “window of opportunity”, with the intention to determine which women are ideal to receive such therapy, on a useful, responsible and safe way. As well, it explains the evolution since the beginning up to date on the hormonal replacement therapy. It is intended, for the reader, to acknowledge some of the principals on the correct use of the therapy. Also, includes a discussion on the benefits on the health of postmenopausal women and its potential side effects. Concluding with an asseveration, that the HRT using the criteria of “window of opportunity” is a way to assure a dignify life for postmenopausal women, knowing that to date where is no ideal HRT, is and will be a controversial topic with many sides.
Keywords
Hormone replacement therapy. estrogens. postmenopause. climacteric.
References
1. Fritz MA, Speroff L. Endocrinología Ginecológica Clínica y Esterilidad. 8 Ed.. Lippincott Williams & Wilkins; 2011.
2. Vermeulen RF, Beurden MV, Kieffer JM, Bleiker EM, Valdimarsdottir HB, Massuger LF, Mourits MJ, Gaarenstroom KN, van Dorst EB, van der Putten HW, Aaronson NK. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. European Journal of Cancer. 2017 Oct;84:159-167. https://doi.org/10.1016/j.ejca.2017.07.018
3. Clinical Guideline on Management of Menopausal Symptoms.www.aafp.org/afp/2014/0901/p338.html#. Accessed 2014 Septiembre 01.
4. Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecologic Oncology. 2016 01;140(1):101-106. https://doi.org/10.1016/j.ygyno.2015.11.016
5. Sturdee DW, Pines A. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011 05 13;14(3):302-320. https://doi.org/10.3109/13697137.2011.570590
6. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012 05 22;15(3):217-228. https://doi.org/10.3109/13697137.2012.656401.
7. Campodónico I. Historia crítica de las terapias de reemplazo hormonal. Una visión particular después del estudio WHI. Rev. Obstet. Ginecol.- Hosp. Santiago Oriente Dr. Luis Tisné Brousse. 2018;13(01):51-53.
8. Hsia J. Conjugated Equine Estrogens and Coronary Heart Disease. Archives of Internal Medicine. 2006 02 13;166(3):357. https://doi.org/10.1001/archinte.166.3.357
9. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. JAMA. 2004 04 14;291(14):1701. https://doi.org/10.1001/jama.291.14.1701
10. Jalava-Broman J, Mäkinen J, Sillanmäki L, Vahtera J, Rautava P. Characteristics associated with initiation of hormone replacement therapy among Finnish women: A register-linkage study. Maturitas. 2016 07;89:73-78. https://doi.org/10.1016/j.maturitas.2016.04.011
11. Agarwal S, Alzahrani F, Ahmed A. Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary?. International Journal of Molecular Sciences. 2018 Oct 14;19(10):3160. https://doi.org/10.3390/ijms19103160
12. Toh S. Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear?. Annals of Internal Medicine. 2010 02 16;152(4):211. https://doi.org/10.7326/0003-4819-152-4-201002160-00005
13. Sarrel PM, Sullivan SD, Nelson LM. Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertility and Sterility. 2016 Dec;106(7):1580-1587. https://doi.org/10.1016/j.fertnstert.2016.09.018
14. 14. Angioli R, Luvero D, Armento G, Capriglione S, Plotti F, Scaletta G, Lopez S, Montera R, Gatti A, Serra GB, Benedetti Panici P, Terranova C. Hormone replacement therapy in cancer survivors: Utopia?. Critical Reviews in Oncology/Hematology. 2018 04;124:51-60. https://doi.org/10.1016/j.critrevonc.2018.02.005
15. O’Donnell RL, Clement KM, Edmondson RJ. Hormone replacement therapy after treatment for a gynaecological malignancy. Current Opinion in Obstetrics and Gynecology. 2016 02;28(1):32-41. https://doi.org/10.1097/gco.0000000000000238
2. Vermeulen RF, Beurden MV, Kieffer JM, Bleiker EM, Valdimarsdottir HB, Massuger LF, Mourits MJ, Gaarenstroom KN, van Dorst EB, van der Putten HW, Aaronson NK. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. European Journal of Cancer. 2017 Oct;84:159-167. https://doi.org/10.1016/j.ejca.2017.07.018
3. Clinical Guideline on Management of Menopausal Symptoms.www.aafp.org/afp/2014/0901/p338.html#. Accessed 2014 Septiembre 01.
4. Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecologic Oncology. 2016 01;140(1):101-106. https://doi.org/10.1016/j.ygyno.2015.11.016
5. Sturdee DW, Pines A. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011 05 13;14(3):302-320. https://doi.org/10.3109/13697137.2011.570590
6. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012 05 22;15(3):217-228. https://doi.org/10.3109/13697137.2012.656401.
7. Campodónico I. Historia crítica de las terapias de reemplazo hormonal. Una visión particular después del estudio WHI. Rev. Obstet. Ginecol.- Hosp. Santiago Oriente Dr. Luis Tisné Brousse. 2018;13(01):51-53.
8. Hsia J. Conjugated Equine Estrogens and Coronary Heart Disease. Archives of Internal Medicine. 2006 02 13;166(3):357. https://doi.org/10.1001/archinte.166.3.357
9. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. JAMA. 2004 04 14;291(14):1701. https://doi.org/10.1001/jama.291.14.1701
10. Jalava-Broman J, Mäkinen J, Sillanmäki L, Vahtera J, Rautava P. Characteristics associated with initiation of hormone replacement therapy among Finnish women: A register-linkage study. Maturitas. 2016 07;89:73-78. https://doi.org/10.1016/j.maturitas.2016.04.011
11. Agarwal S, Alzahrani F, Ahmed A. Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary?. International Journal of Molecular Sciences. 2018 Oct 14;19(10):3160. https://doi.org/10.3390/ijms19103160
12. Toh S. Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear?. Annals of Internal Medicine. 2010 02 16;152(4):211. https://doi.org/10.7326/0003-4819-152-4-201002160-00005
13. Sarrel PM, Sullivan SD, Nelson LM. Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertility and Sterility. 2016 Dec;106(7):1580-1587. https://doi.org/10.1016/j.fertnstert.2016.09.018
14. 14. Angioli R, Luvero D, Armento G, Capriglione S, Plotti F, Scaletta G, Lopez S, Montera R, Gatti A, Serra GB, Benedetti Panici P, Terranova C. Hormone replacement therapy in cancer survivors: Utopia?. Critical Reviews in Oncology/Hematology. 2018 04;124:51-60. https://doi.org/10.1016/j.critrevonc.2018.02.005
15. O’Donnell RL, Clement KM, Edmondson RJ. Hormone replacement therapy after treatment for a gynaecological malignancy. Current Opinion in Obstetrics and Gynecology. 2016 02;28(1):32-41. https://doi.org/10.1097/gco.0000000000000238
Downloads
Download data is not yet available.